JP Morgan Maintains Overweight on CVS Health, Lowers Price Target to $86
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Lisa Gill maintains an Overweight rating on CVS Health (NYSE:CVS) but lowers the price target from $101 to $86.
May 30, 2024 | 6:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Lisa Gill maintains an Overweight rating on CVS Health but lowers the price target from $101 to $86.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100